At a glance
ClinicalIndex Comparison RecordN/ACompleted· 476 enrolled
Drug / intervention
Azithromycindrug
Likely dose
Azithromycin 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Use Investigation On Zithromac Tablets 600mg In HIV Patients (Post Marketing Commitment Plan)
In Brief
An observational study evaluating Azithromycin for HIV Infection. Completed, enrolled 476 participants.
Detailed Summary
The investigation will be conducted for the purpose of determining the condition of occurrence of Adverse Events under the actual post-marketing use of Zithromac 600mg Tablet, verifying the therapeutic effects, detecting unknown Adverse Drug Reactions and drug interactions and determining the factors affecting safety and efficacy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
Countries--
CollaboratorsAltmarc Inc.
Timeline
N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2002
First PostedOct 2010
Primary CompletionMar 2012
TodayJul 2026
First PostedOct 25, 2010
Enrollment StartJul 1, 2002
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 15.7 years ago
Interventions
Azithromycindrug
Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults. Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.